Adma生物製品 ADMA 深 滬
已收盤 02-06 16:00:00 美东时间
16.43
+0.490
+3.07%
華盛通- 最 高16.60
- 今 開16.31
- 成交量 158.85万股
- 最 低 16.09
- 昨 收 15.94
- 總市值 39.10亿
- 52周最高 25.67
- 市盈率 靜 20.23
- 換手率 0.67%
- 52周最低 13.50
- 委 比 -89.89%
- 總股本 2.38亿
- 歷史最高 25.67
- 量 比 0.75
- 振 幅 3.20%
- 歷史最低 1.01
- 每 手 1
- 風險率 2.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ADMA Biologics Reports Preliminary FY25 Revenue Range $510M - $511M, FY26 Total Revenue Expected ~$635M
ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), a U.S. based end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its
01-12 21:08
ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update
ADMA Biologics announced preliminary FY2025 revenue of $510–511 million, meeting or exceeding prior guidance, with cash growing to $88 million and operating cash flow of ~$40 million in Q4 2025. FY2026 and FY2027 revenue expected to reach $635 million and $775 million, respectively, with EBITDA targets of $360 million and $455 million. Strategic initiatives, including yield-enhanced production and plasma network optimization, support margin expan...
01-12 13:00
ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026
ADMA Biologics CEO Adam Grossman will present at the J.P. Morgan Healthcare Conference on January 12, 2026, at 9:45 a.m. PT. A live audio webcast will be available on the Company’s website, with an archived version posted afterward. ADMA Biologics specializes in manufacturing, marketing, and developing plasma-derived biologics for immunodeficient patients and those at risk for infectious diseases. Its portfolio includes ASCENIV™, BIVIGAM®, and NA...
01-05 12:00
Enova, eToro, NP, SLM among week's biggest financials movers
Financial stocks (XLF) largely drifted higher, while the broader S&P 500 slipped in the past week, which was marked by the Federal Reserve's third consecutive interest-rate cut. Enova International (E...
2025-12-13 23:10
What's Driving the Market Sentiment Around ADMA Biologics Inc?
ADMA Biologics Inc's (NYSE:ADMA) short interest as a percent of float has falle...
2025-11-25 03:00
ADMA Biologics Q3 EPS $0.15, Inline, Sales $134.224M Beat $130.533M Estimate
ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.15 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $134.224
2025-11-06 05:12
美股盘后 | ADMA生物制剂跌10.25%
ADMA生物制剂预计在2025年第二季度公布财报，市场分析师预期其每股收益为0.14美元，季度营收将达1.215亿美元。
2025-08-07 06:27
ADMA Biologics shares are trading lower after the company reported worse-than-expected Q2 revenue results and issued FY26 revenue guidance below estimates.
ADMA Biologics shares are trading lower after the company reported worse-than-e...
2025-08-07 04:57
ADMA Biologics Sees FY2026 Sales $500.000M-$625.000M vs $641.17M Est
ADMA Biologics (NASDAQ:ADMA) sees FY2026 sales of $500.000 million-$625.000 million vs $641.17 million analyst estimate.
2025-08-07 04:43
ADMA Biologics Secures $300M Credit Agreement with JPMorgan
ADMA Biologics ( ($ADMA) ) has provided an update. On August 5, 2025, ADMA Biol...
2025-08-07 04:38
